{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:08:53Z","timestamp":1790518133505,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Plague is a rare and severe zoonotic illness with limited empiric evidence to support treatment recommendations. We summarize treatment information for all patients with plague in the United States (US) as collected under the auspices of public health surveillance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed use of specific antimicrobials and illness outcome among cases of plague reported from 1942\u20132018. Antimicrobials were a priori classified into high-efficacy (aminoglycosides, tetracyclines, fluoroquinolones, sulfonamides, and chloramphenicol) and limited-efficacy classes (all others). Logistic regression models were created to describe associations between use of specific antimicrobial classes and illness outcome while controlling for potential confounding factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 533 total reported plague cases during 1942\u20132018, 426 (80%) received high-efficacy antimicrobial therapy. Mortality differed significantly among those receiving high-efficacy therapy (9%) and only limited-efficacy therapy (51%). Aminoglycosides and tetracyclines were used more commonly than other classes, and their use was associated with increased odds of survival of plague. Gentamicin use was associated with higher mortality than streptomycin, and aminoglycoside use was linked to higher mortality than for tetracyclines. Fluoroquinolones have been used in treatment of &amp;gt;30% of patients in recent years and limited data suggest clinical effectiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Most US patients with plague have received effective antimicrobials. Aminoglycosides and tetracyclines substantially improve survival of plague, and fluoroquinolones may be equally as effective, yet lack sufficient data. Early recognition and early treatment with any of these antimicrobial classes remain the most important steps to improving survival of plague.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1227","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T20:19:43Z","timestamp":1578082783000},"page":"S20-S26","source":"Crossref","is-referenced-by-count":25,"title":["Antimicrobial Treatment Patterns and Illness Outcome Among United States Patients With Plague, 1942\u20132018"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-6688","authenticated-orcid":false,"given":"Kiersten J","family":"Kugeler","sequence":"first","affiliation":[{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Mead","sequence":"additional","affiliation":[{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie B","family":"Campbell","sequence":"additional","affiliation":[{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A","family":"Nelson","sequence":"additional","affiliation":[{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"2021041413235437100_CIT0001","volume-title":"Plague","author":"Pollitzer","year":"1954"},{"key":"2021041413235437100_CIT0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2014etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"2021041413235437100_CIT0003","volume-title":"Plague manual: epidemiology, distribution, surveillance and control","author":"Dennis","year":"1999"},{"key":"2021041413235437100_CIT0004","first-page":"2607","article-title":"Yersinia species (including plague).","volume-title":"Principles and practice of infectious diseases","author":"Mead","year":"2015","edition":"8th"},{"key":"2021041413235437100_CIT0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3201\/eid2101.140564","article-title":"Epidemiology of human plague in the United States, 1900\u20132012","volume":"21","author":"Kugeler","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021041413235437100_CIT0006","first-page":"23","article-title":"Successful treatment of human plague with oral ciprofloxacin","author":"Apangu","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2021041413235437100_CIT0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1086\/381545","article-title":"Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985\u20131999","volume":"38","author":"Boulanger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021041413235437100_CIT0008","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1086\/500137","article-title":"Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania","volume":"42","author":"Mwengee","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021041413235437100_CIT0009","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"2021041413235437100_CIT0010","first-page":"489","article-title":"Recent advances in the treatment of bubonic plague","author":"Wagle","year":"1948","journal-title":"Indian J Med Sci"},{"key":"2021041413235437100_CIT0011","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jama.1950.02920120006003","article-title":"Modern therapy of plague","volume":"144","author":"Meyer","year":"1950","journal-title":"J Am Med Assoc"},{"key":"2021041413235437100_CIT0012","first-page":"637","article-title":"Treatment of bubonic plague with sulfonamides and antibiotics","volume":"9","author":"Sokhey","year":"1953","journal-title":"Bull World Health Organ"},{"key":"2021041413235437100_CIT0013","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1128\/AAC.01481-10","article-title":"In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis","volume":"55","author":"Wendte","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041413235437100_CIT0014","first-page":"305","article-title":"Aminoglycosides.","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"Leggett","year":"2020","edition":"9th"},{"key":"2021041413235437100_CIT0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/AAC.05043-11","article-title":"Lack of antimicrobial resistance in Yersinia pestis isolates from 17 countries in the Americas, Africa, and Asia","volume":"56","author":"Urich","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041413235437100_CIT0016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3201\/eid0701.010106","article-title":"Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis","volume":"7","author":"Guiyoule","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"2021041413235437100_CIT0017","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/AAC.42.3.675","article-title":"Antibiotic treatment of experimental pneumonic plague in mice","volume":"42","author":"Byrne","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041413235437100_CIT0018","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archinte.1992.00400180107017","article-title":"Plague. A clinical review of 27 cases","volume":"152","author":"Crook","year":"1992","journal-title":"Arch Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/Supplement_1\/S20\/37058967\/ciz1227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/Supplement_1\/S20\/37058967\/ciz1227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T17:34:23Z","timestamp":1618594463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/Supplement_1\/S20\/5841432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":18,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,5,21]]},"published-print":{"date-parts":[[2020,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1227","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2020,5,1]]}}}